Answers are grounded in this paper and cite their sources.
Rituximab (RTX), an anti-CD20 monoclonal antibody, was highly efficacious in reducing relapse rates in neuromyelitis optica (NMO) in several observational case series.1–7,e1-e3 Despite the favorable record, most series include 1 or more patients who experienced a relapse shortly after RTX induction.2,5,7,e1,e4-e6 We review clinical histories of 6 patients with NMO treated at the New York University Multiple Sclerosis Center who experienced a relapse within 1 week of RTX induction and discuss potential biological mechanisms that may account for apparent disease rebound. Acknowledgment: The authors thank Dr. Adil Javed for sharing his experience with rituximab in NMO, Dr Bibiana Bielekova for insightful comments, and Prof. Markus Reindl for carrying out anti-MOG antibody testing on patient 3. The authors are grateful to Ms. Tamar Bacon for her help with preparation of the figures.
No takes yet. Share an insight, caveat, or question.
Perumal et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: